TriSalus Life Sciences, Inc.
TLSI
$6.45
-$0.55-7.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.44% | 20.12% | -2.64% | -321.34% | 44.62% |
| Total Depreciation and Amortization | -1.21% | -4.07% | -10.88% | 6.04% | -6.19% |
| Total Amortization of Deferred Charges | 7.00% | 9.36% | 32.02% | 6.59% | -37.45% |
| Total Other Non-Cash Items | 121.15% | -50.03% | 8.62% | 163.13% | -77.99% |
| Change in Net Operating Assets | 271.97% | -186.80% | 242.40% | 114.81% | 50.58% |
| Cash from Operations | 49.33% | -62.70% | 21.17% | 47.39% | 19.18% |
| Capital Expenditure | -332.26% | 112.33% | -1,408.00% | 70.41% | -181.67% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -289.25% | 113.03% | -1,328.00% | 70.41% | -181.67% |
| Total Debt Issued | -- | -100.00% | -- | -- | -100.00% |
| Total Debt Repaid | -500.00% | 98.59% | -273.68% | 13.64% | -4.76% |
| Issuance of Common Stock | -99.60% | 7,881.00% | -90.74% | -48.45% | 62.05% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -197.88% | -- | -- | 100.00% |
| Cash from Financing | -99.60% | 113.84% | 223.58% | -48.58% | -77.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -128.19% | 201.45% | 261.96% | 46.79% | -141.51% |